Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir versus molnupiravir for COVID-19
TCTR20230111009Phase 3Completed
- Sponsor
- National Science and Technology Development Agency
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of favipiravir, molnupiravir in coronavirus disease 2019 (COVID-19), sponsored by National Science and Technology Development Agency. Started Jul 2022; status: completed.
02
Drugs
favipiravirmolnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20230111009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230111009.